Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Yap, Ning Yi ^a   Rajandram, Retnagowri ^a,b   Ng, Keng Lim ^a,b   Pailoor, Jayalakshmi ^a   Fadzli, Ahmad ^a   Gobe, Glenda Carolyn ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; FUMARATE HYDRATASE; PROTEIN; RAS ASSOCIATION DOMAIN FAMILY 1A PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; GENETIC MARKER;

ADENOMA; CANCER PROGNOSIS; CHROMATIN; CHROMOPHOBE RENAL CELL CARCINOMA; CHROMOSOME 17; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 3; CLEAR CELL TUBULOPAPILLARY RENAL CELL CARCINOMA; COLLECTING DUCT RENAL CELL CARCINOMA; DIFFERENTIAL DIAGNOSIS; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY TUMOR; MEDULLARY CARCINOMA; METANEPHRIC ADENOMA; MUCINOUS TUBULAR AND SPINDLE CELL CARCINOMA; ONCOCYTOMA; PAPILLARY CARCINOMA; PAPILLARY RENAL CELL CARCINOMA; PROTO ONCOGENE; RENAL MEDULLARY CARCINOMA; RENAL ONCOCYTOMA; REVIEW; SPINDLE CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUBULOCYSTIC RENAL CELL CARCINOMA; UPPER URINARY TRACT UROTHELIAL CARCINOMA; CARCINOMA, RENAL CELL; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; KIDNEY NEOPLASMS; MUTATION; PREVALENCE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

CARCINOMA, RENAL CELL; CHROMOSOME ABERRATIONS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY NEOPLASMS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84942749582     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/476508     Document Type: Review

References (264)

1. M. Sun, R. Thuret, F. Abdollah et al., "Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis, " European Urology, vol. 59, no. 1, pp. 135-141, 2011.
2. N. Y. Yap, K. L. Ng, T. A. Ong et al., "Clinical prognostic factors and survival outcome in renal cell carcinoma patients - a Malaysian single centre perspective, " Asian Pacific Journal of Cancer Prevention, vol. 14, no. 12, pp. 7497-7500, 2013.
3. A. Znaor, J. Lortet-Tieulent, A. Jemal, andF.Bray, "International variations and trends in testicular cancer incidence and mortality, " European Urology, vol. 65, no. 6, pp. 1095-1106, 2014.
4. K. L. Ng, R. Rajandram, C. Morais et al., "Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem?" Journal of Clinical Pathology, vol. 67, no. 2, pp. 97-104, 2014.
5. D.Hanahan and R. A.Weinberg, "Hallmarks of cancer: the next generation, " Cell, vol. 144, no. 5, pp. 646-674, 2011.
6. B.Vogelstein and K.W. Kinzler, "Cancer genes and the pathways they control, " Nature Medicine, vol. 10, no. 8, pp. 789-799, 2004.
7. T. Sjöblom, "Systematic analyses of the cancer genome: lessons learned fromsequencingmost of the annotated human proteincoding genes, " Current Opinion in Oncology, vol. 20, no. 1, pp. 66-71, 2008.
8. A. Salvi, E. Marchina, A. Benetti, P. Grigolato, G. de Petro, and S. Barlati, "Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients, " International Journal of Oncology, vol. 33, no. 2, pp. 271-276, 2008.
9. S. Richard, R. Lidereau, and S. Giraud, "The growing family of hereditary renal cell carcinoma, "NephrologyDialysis Transplantation, vol. 19, no. 12, pp. 2954-2958, 2004.
10. C. S.Ng, C.G.Wood, P.M. Silverman, N.M. Tannir, P. Tamboli, and C. M. Sandler, "Renal cell carcinoma: diagnosis, staging, and surveillance, " American Journal of Roentgenology, vol. 191, no. 4, pp. 1220-1232, 2008.
11. F. Algaba, H.Akaza, A. López-Beltrán et al., "Current pathology keys of renal cell carcinoma, " European Urology, vol. 60, no. 4, pp. 634-643, 2011.
12. B. C. Leibovich, C. M. Lohse, P. L. Crispen et al., "Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma, " Journal of Urology, vol. 183, no. 4, pp. 1309-1316, 2010.
13. J.-J. Patard, E. Leray, N. Rioux-Leclercq et al., "Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience, " Journal of Clinical Oncology, vol. 23, no. 12, pp. 2763-2771, 2005.
14. V. Ficarra, G. Martignoni, A. Galfano et al., "Prognostic role of the histologic subtypes of renal cell carcinoma after slide revision, " European Urology, vol. 50, no. 4, pp. 786-794, 2006.
15. K. Foster, P. A. Crossey, P. Cairns et al., "Molecular genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p, 5q, 11p, 17 and 22, " British Journal of Cancer, vol. 69, no. 2, pp. 230-234, 1994.
16. J. C. Strefford, I. Stasevich, T. M. Lane, Y.-J. Lu, T. Oliver, and B. D. Young, "A combination of molecular cytogenetic analyses reveals complex genetic alterations in conventional renal cell carcinoma, " Cancer Genetics and Cytogenetics, vol. 159, no. 1, pp. 1-9, 2005.
17. M. I. Toma, M. Grosser, A. Herr et al., "Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array, " Neoplasia, vol. 10, no. 7, pp.634-642, 2008.
18. F. Latif, K. Tory, J. Gnarra et al., "Identification of the von Hippel-Lindau disease tumor suppressor gene, " Science, vol. 260, no. 5112, pp. 1317-1320, 1993.
19. S. Richard, B. Gardie, S. Couvé, and S. Gad, "Von Hippel-Lindau: howa rare disease illuminates cancer biology, " Seminars in Cancer Biology, vol. 23, no. 1, pp. 26-37, 2013.
20. C. A. Friedrich, "VonHippel-Lindau syndrome. A pleomorphic condition, " Cancer, vol. 86, no. 11, pp. 2478-2482, 1999.
21. H. P.H.Neumann, B.U.Bender, D. P. Berger et al., "Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma, " Journal of Urology, vol. 160, no. 4, pp. 1248-1254, 1998.
22. M. Krieg, R. Haas, H. Brauch, T. Acker, I. Flamme, and K. H. Plate, "Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function, " Oncogene, vol. 19, no. 48, pp. 5435-5443, 2000.
23. P. H.Maxwell, M. S.Wlesener, G.W. Chang et al., "The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis, " Nature, vol. 399, no. 6733, pp. 271-275, 1999.
24. M. E. Cockman, N. Masson, D. R. Mole et al., "Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumour suppressor protein, " The Journal of Biological Chemistry, vol. 275, no. 33, pp. 25733-25741, 2000.
25. J. Bellmunt, "Current treatment in advanced renal cell carcinoma (RCC): impact of targeted therapies in the management of RCC, " European Urology Supplements, vol. 6, no. 7, pp. 484-491, 2007.
26. P. Staller, J. Sulitkova, J. Lisztwan, H. Moch, E. J. Oakeley, and W. Krek, "Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL, " Nature, vol. 425, no. 6955, pp. 307-311, 2003.
27. N. de Paulsen, A. Brychzy, M. C. Fournier et al., "Role of transforming growth factor-α in von Hippel-Lindau (VHL)-/- clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis, " Proceedings of theNationalAcademy of Sciences of theUnited States of America, vol. 98, no. 4, pp. 1387-1392, 2001.
28. W. Y. Kim and W. G. Kaelin, "Role of VHL gene mutation in human cancer, " Journal of Clinical Oncology, vol. 22, no. 24, pp. 4991-5004, 2004.
29. A.G. Knudson Jr., L. C. Strong, and D. E. Anderson, "Heredity and cancer in man, " Progress inMedical Genetics, vol. 9, pp. 113-158, 1973.
30. K. Kondo, M. Yao, M. Yoshida et al., "Comprehensive mutational analysis of theVHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters, " Genes Chromosomes and Cancer, vol. 34, no. 1, pp. 58-68, 2002.
31. K. P. vanHouwelingen, B. A. C. vanDijk, C. A. Hulsbergen-van de Kaa et al., "Prevalence of von Hippel-Lindau genemutations in sporadic renal cell carcinoma: results from The Netherlands cohort study, " BMC Cancer, vol. 5, article 57, 2005.
32. C.Gallou, D. Joly, A. Méjean et al., "Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC, " HumanMutation, vol. 13, no. 6, pp. 464-475, 1999.
33. H. Moch, P. Schraml, L. Bubendorf et al., "Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal cell carcinoma detected by fluorescence in situ hybridization, " Cancer Research, vol. 58, no. 11, pp. 2304-2309, 1998.
34. S. C. Clifford, A. H. Prowse, N. A. Affara, C. H. C. M. Buys, and E. R.Maher, "Inactivation of the vonHippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHLindependent pathway in clear cell renal tumourigenesis, " Genes Chromosomes and Cancer, vol. 22, no. 3, pp. 200-209, 1998.
35. P. Schraml, K. Struckmann, F. Hatz et al., "VHL mutations and their correlationwith tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma, " The Journal of Pathology, vol. 196, no. 2, pp. 186-193, 2002.
36. K. M. Smits, L. J. Schouten, B. A. C. van Dijk et al., "Genetic and epigenetic alterations in the von Hippel-Lindau gene: the influence on renal cancer prognosis, " Clinical Cancer Research, vol. 14, no. 3, pp. 782-787, 2008.
37. M. R. Alves, F. C. Carneiro, A. M. Lavorato-Rocha et al., "Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma, " Virchows Archiv, vol. 465, no. 3, pp. 321-330, 2014.
38. M. M. Baldewijns, I. J. H. van Vlodrop, K. M. Smits et al., "Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene, " Cellular Oncology, vol. 31, no. 5, pp. 371-382, 2009.
39. H. Brauch, G. Weirich, J. Brieger et al., "VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation, " Cancer Research, vol. 60, no. 7, pp. 1942-1948, 2000.
40. A. C. Young, R. A. Craven, D. Cohen et al., "Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma, " Clinical Cancer Research, vol. 15, no. 24, pp. 7582-7592, 2009.
41. A. S. Parker, J. C. Cheville, C.M. Lohse, T. Igel, B. C. Leibovich, and M. L. Blute, "Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma, " Urology, vol. 65, no. 6, pp. 1090-1095, 2005.
42. J.-J. Patard, P. Fergelot, P. I. Karakiewicz et al., "Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma, " International Journal of Cancer, vol. 123, no. 2, pp. 395-400, 2008.
43. M. Yao, M. Yoshida, T. Kishida et al., "VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma, " Journal of the National Cancer Institute, vol. 94, no. 20, pp. 1569-1575, 2002.
44. J.-J. Patard, N. Rioux-Leclercq, D. Masson et al., "Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma, " British Journal of Cancer, vol. 101, no. 8, pp. 1417-1424, 2009.
45. M.N. Fishman, "Targeted therapy of kidney cancer: keeping the art around the algorithms, " Cancer Control, vol. 20, no. 3, pp. 222-232, 2013.
46. A. V. Soerensen, F. Donskov, G. G. Hermann et al., "Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2, " European Journal of Cancer, vol. 50, no. 3, pp. 553-562, 2014.
47. R. A. Nelson, N. Vogelzang, and S. K. Pal, "A gap in diseasespecific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a seer database analysis, " Clinical Genitourinary Cancer, vol. 11, no. 3, pp. 303-310, 2013.
48. A. J. Cohen, F. P. Li, S. Berg et al., "Hereditary renal-cell carcinoma associated with a chromosomal translocation, " The New England Journal of Medicine, vol. 301, no. 11, pp. 592-595, 1979.
49. D. Bodmer, M. Eleveld, M. Ligtenberg et al., "Cytogenetic and molecular analysis of early stage renal cell carcinomas in a family with a translocation (2;3)(q35;q21), " Cancer Genetics and Cytogenetics, vol. 134, no. 1, pp. 6-12, 2002.
50. J. Chen, W.-O. Lui, M. D. Vos et al., "The t(1;3) breakpointspanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas, " Cancer Cell, vol. 4, no. 5, pp. 405-413, 2003.
51. J. Podolski, T. Byrski, S. Zajaczek et al., "Characterization of a familial RCC-associated t(2;3)(q33;q21) chromosome translocation, " Journal of Human Genetics, vol. 46, no. 12, pp. 685-693, 2001.
52. B. Meléndez, S. Rodríguez-Perales, B. Martínez-Delgado et al., "Molecular study of a new family with hereditary renal cell carcinoma and a translocation t(3;8)(p13;q24.1), " Human Genetics, vol. 112, no. 2, pp. 178-185, 2003.
53. M. J. Eleveld, D. Bodmer, G.Merkx et al., "Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15), " Genes Chromosomes and Cancer, vol. 31, no. 1, pp. 23-32, 2001.
54. A. C. M. Bonné, D. Bodmer, E. F. P. M. Shoenmakers, C. M. van Ravenswaaij, N. Hoogerbrugge, and A. G. van Kessel, "Chromosome 3 translocations and familial renal cell cancer, " Current Molecular Medicine, vol. 4, no. 8, pp. 849-854, 2004.
55. G. Kovacs, P. Brusa, and W. De Riese, "Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas, " International Journal of Cancer, vol. 43, no. 3, pp. 422-427, 1989.
56. R. P. Kuiper, L. Vreede, R. Venkatachalam et al., "The tumour suppressor gene FBXW7 is disrupted by a constitutional t(3; 4)(q21; q31) in a patient with renal cell cancer, " Cancer Genetics and Cytogenetics, vol. 195, no. 2, pp. 105-111, 2009.
57. A. G. van Kessel Geurts, H. Wijnhoven, D. Bodmer et al., "Renal cell cancer: chromosome 3 translocations as risk factors, " Journal of the National Cancer Institute, vol. 91, no. 13, pp. 1159-1160, 1999.
58. R. E. Foster, M. Abdulrahman, M. R. Morris et al., "Characterization of a 3;6 translocation associated with renal cell carcinoma, " Genes Chromosomes and Cancer, vol. 46, no. 4, pp. 311-317, 2007.
59. D. Bodmer, M. J. Eleveld, M. J. L. Ligtenberg et al., "An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation, "TheAmerican Journal ofHumanGenetics, vol. 62, no. 6, pp. 1475-1483, 1998.
60. A.Martinez, P. Fullwood, K. Kondo et al., "Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis, "The Journal of Clinical Pathology - Molecular Pathology, vol. 53, no. 3, pp. 137-144, 2000.
61. F. P. Li, H.-J. H. Decker, B. Zbar et al., "Clinical and genetic studies of renal cell carcinomas in a family with a constitutional chromosome 3;8 translocation. Genetics of familial renal carcinoma, " Annals of Internal Medicine, vol. 118, no. 2, pp. 106-111, 1993.
62. T. Druck, K. Kastury, P. Hadaczek et al., "Loss of heterozygosity at the familial RCC t(3;8) locus in most clear cell renal carcinomas, " Cancer Research, vol. 55, no. 22, pp. 5348-5353, 1995.
63. F. Sükösd, N. Kuroda, T. Beothe, A. P. Kaur, and G. Kovacs, "Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma, " Cancer Research, vol. 63, no. 2, pp. 455-457, 2003.
64. R. B. Singh and P. S. Amare Kadam, "Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC), " Urologic Oncology, vol. 31, no. 7, pp. 1333-1342, 2013.
65. G. Toledo, J. J. Sola, M.D. Lozano, E. Soria, and J. Pardo, "Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer, " Modern Pathology, vol. 17, no. 4, pp. 440-448, 2004.
66. A. Vecchione, C. Sevignani, E. Giarnieri et al., "Inactivation of the FHIT gene favors bladder cancer development, " Clinical Cancer Research, vol. 10, no. 22, pp. 7607-7612, 2004.
67. Q. Yang, M. Nakamura, Y. Nakamura et al., "Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer, " Clinical Cancer Research, vol. 8, no. 9, pp. 2890-2893, 2002.
68. C. Huiping, S. Kristjansdottir, J. T. Bergthorsson et al., "High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer, " European Journal of Cancer, vol. 38, no. 5, pp. 728-735, 2002.
69. D.Butler, C. Collins, M.Mabruk, C.B.Walsh, M.B. Leader, and E.W. Kay, "Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features, " Journal of Pathology, vol. 192, no. 4, pp. 502-510, 2000.
70. V. Shridhar, L. Wang, R. Rosati et al., "Frequent breakpoints in the region surrounding FRA3B in sporadic renal cell carcinomas, " Oncogene, vol. 14, no. 11, pp. 1269-1277, 1997.
71. J. R. Karras, C.A. Paisie, and K.Huebner, "Replicative stress and the FHIT gene: roles in tumor suppression, genomestability and prevention of carcinogenesis, " Cancers, vol. 6, no. 2, pp. 1208-1219, 2014.
72. P. Hadaczek, A. L. Kovatich, J. Gronwald, J. Lubinski, K. Huebner, and P. A.Mccue, "Loss or reduction of Fhit expression in renal neoplasias: correlation with histogenic class, " Human Pathology, vol. 30, no. 11, pp. 1276-1283, 1999.
73. U. Ramp, E. Caliskan, T. Ebert et al., "FHIT expression in clear cell renal carcinomas: versatility of protein levels and correlation with survival, " Journal of Pathology, vol. 196, no. 4, pp. 430-436, 2002.
74. E. J. Eyzaguirre, M. Miettinen, B. A. Norris, and Z. Gatalica, "Different immunohistochemical patterns of Fhit protein expression in renal neoplasms, " Modern Pathology, vol. 12, no. 10, pp. 979-983, 1999.
75. N. Zanesi, V. Fidanza, L. Y. Fong et al., "The tumor spectrum in FHIT-deficient mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 18, pp. 10250-10255, 2001.
76. T. Fujishita, Y.Doi, M. Sonoshita et al., "Development of spontaneous tumours and intestinal lesions in Fhit gene knockout mice, " British Journal of Cancer, vol. 91, no. 8, pp. 1571-1574, 2004.
77. P. Hadaczek, Z. Siprashvili, M. Markiewski et al., "Absence or reduction of FHIT expression in most clear cell renal carcinomas, " Cancer Research, vol. 58, no. 14, pp. 2946-2951, 1998.
78. M. Velickovic, B. Delahunt, and S. K. G. Grebe, "Loss of heterozygosity at 3p14.2 in clear cell renal cell carcinoma is an early event and is highly localized to the FHIT gene locus, " Cancer Research, vol. 59, no. 6, pp. 1323-1326, 1999.
79. H. Donninger, J. A. Clark, M. K.Monaghan, M. L. Schmidt, M. Vos, and G. J. Clark, "Cell cycle restriction is more important than apoptosis induction for RASSF1A protein tumor suppression, " The Journal of Biological Chemistry, vol. 289, no. 45, pp. 31287-31295, 2014.
80. L. Shivakumar, J. Minna, T. Sakamaki, R. Pestell, and M. A. White, "The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation, " Molecular and Cellular Biology, vol. 22, no. 12, pp. 4309-4318, 2002.
81. J.-H. Yoon, R. Dammann, and G. P. Pfeifer, "Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas, " International Journal of Cancer, vol. 94, no. 2, pp. 212-217, 2001.
82. W. Yeo, W. L. Wong, N. Wong, B. K. Law, G. M. Tse, and S. Zhong, "High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer, " Pathology, vol. 37, no. 2, pp. 125-130, 2005.
83. N. Yanagawa, G. Tamura, H. Oizumi et al., "Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers, " Lung Cancer, vol. 58, no. 1, pp. 131-138, 2007.
84. I. Peters, K. Rehmet, N. Wilke et al., "RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis, " Molecular Cancer, vol. 6, article 49, 2007.
85. Y. Kawai, S. Sakano, Y. Suehiro et al., "Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma, " Annals of Oncology, vol. 21, no. 8, pp. 1612-1617, 2010.
86. V. I. Loginov, D. S. Khodyrev, I. V. Pronina et al., "Methylation of promoter region of RASSF1A gene and frequencies of allelic imbalances in chromosome 3 critical regions are correlatedwith progression of clear cell renal cell carcinoma, " Molekuliarnaia Biologiia, vol. 43, no. 3, pp. 429-438, 2009.
87. H. Tezval, A. S. Merseburger, I. Matuschek, S. Machtens, M. A. Kuczyk, and J. Serth, "RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma, " BMC Urology, vol. 8, article 12, 2008.
88. C. Morrissey, A. Martinez, M. Zatyka et al., "Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma, " Cancer Research, vol. 61, no. 19, pp. 7277-7281, 2001.
89. G. Duns, R. M. W. Hofstra, J. G. Sietzema et al., "Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development, " HumanMutation, vol. 33, no. 7, pp. 1059-1062, 2012.
90. I.Varela, P. Tarpey, K. Raine et al., "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma, " Nature, vol. 469, no. 7331, pp. 539-542, 2011.
91. S. Peña-Llopis, S. Vega-Rubín-De-Celis, A. Liao et al., "BAP1 loss defines a newclass of renal cell carcinoma, "Nature Genetics, vol. 44, no. 7, pp. 751-759, 2012.
92. A. A.Hakimi, Y.-B.Chen, J.Wren et al., "Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma, " European Urology, vol. 63, no. 5, pp. 848-854, 2013.
93. Z. Lichner, A. Scorilas, N. M. A. White et al., "The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma, " The American Journal of Pathology, vol. 182, no. 4, pp. 1163-1170, 2013.
94. L. Liao, J. R. Testa, and H. Yang, "The roles of chromatinremodelers and epigenetic modifiers in kidney cancer, " Cancer Genetics, 2015.
95. M.Gerlinger, S.Horswell, J. Larkin et al., "Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing, " Nature Genetics, vol. 46, no. 3, pp. 225-233, 2014.
96. A. Sankin, A. A. Hakimi, N. Mikkilineni et al., "The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling, " Cancer Medicine, vol. 3, no. 6, pp. 1485-1492, 2014.
97. P. R. Benusiglio, S. Couve, B. Gilbert-Dussardier et al., "A germline mutation in PBRM1 predisposes to renal cell carcinoma, " Journal of Medical Genetics, vol. 52, no. 6, pp. 426-430, 2015.
98. M. N. Farley, L. S. Schmidt, J. L.Mester et al., "A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma, " Molecular Cancer Research, vol. 11, no. 9, pp. 1061-1071, 2013.
99. T. Popova, L.Hebert, V. Jacquemin et al., "Germline BAP1mutations predispose to renal cell carcinomas, " American Journal of Human Genetics, vol. 92, no. 6, pp. 974-980, 2013.
100. J. Stein, M.Majores, M. Rohde et al., "KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostatespecific antigen-relapse following radical prostatectomy, " The American Journal of Pathology, vol. 184, no. 9, pp. 2430-2437, 2014.
101. A. Mamo, L. Cavallone, S. Tuzmen et al., "An integrated genomic approach identifies ARID1A as a candidate tumorsuppressor gene in breast cancer, " Oncogene, vol. 31, no. 16, pp. 2090-2100, 2012.
102. W. Al Sarakbi, W. Sasi, W. G. Jiang, T. Roberts, R. F. Newbold, and K. Mokbel, "The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters, " BMC Cancer, vol. 9, no. 1, article 290, 2009.
103. R. Pawłowski, S. M. Mühl, T. Sulser, W. Krek, H.Moch, and P. Schraml, "Loss of PBRM1 expression is associated with renal cell carcinoma progression, " International Journal of Cancer, vol. 132, no. 2, pp. E11-E17, 2013.
104. W. H. da Costa, M. Rezende, F. C. Carneiro et al., "Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma, " BJU International, vol. 113, no. 5b, pp. E157-E163, 2014.
105. A. A.Hakimi, I.Ostrovnaya, B.Reva et al., "Adverseoutcomes in clear cell renal cell carcinoma withmutations of 3p21 epigenetic regulators BAP1 and SETD2: A report byMSKCC and the KIRC TCGA research network, " Clinical Cancer Research, vol. 19, no. 12, pp. 3259-3267, 2013.
106. Y. Sato, T. Yoshizato, Y. Shiraishi et al., "Integrated molecular analysis of clear-cell renal cell carcinoma, " Nature Genetics, vol. 45, no. 8, pp. 860-867, 2013.
107. P. Kapur, A. Christie, J. D. Raman et al., "BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma, " Journal of Urology, vol. 191, no. 3, pp. 603-610, 2014.
108. L. Albiges, J. Guegan, A. Le Formal et al., "MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array, " Clinical Cancer Research, vol. 20, no. 13, pp. 3411-3421, 2014.
109. L. Gossage, M.Murtaza, A. F. Slatter et al., "Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma, " Genes Chromosomes and Cancer, vol. 53, no. 1, pp. 38-51, 2014.
110. P. Kapur, S. Peña-Llopis, A. Christie et al., "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation, " The Lancet Oncology, vol. 14, no. 2, pp. 159-167, 2013.
111. J. H. Park, C. Lee, J. H. Suh, J. Y. Chae, H. W. Kim, and K. C. Moon, "Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma, " Human Pathology, vol. 46, no. 3, pp. 454-460, 2015.
112. K. Nagao, S. Yoshihiro, H. Matsuyama, S. Yamaguchi, K. Oba, and K. Naito, "Clinical significance of allelic loss of chromosome region 5q22.3 approximately q23.2 in nonpapillary renal cell carcinoma, " Cancer Genetics and Cytogenetics, vol. 136, no. 1, pp. 23-30, 2002.
113. K. Nagao, S. Yamaguchi, H. Matsuyama et al., "Allelic loss of 3p25 associated with alterations of 5q22.3∼q23.2 may affect the prognosis of conventional renal cell carcinoma, " Cancer Genetics and Cytogenetics, vol. 160, no. 1, pp. 43-48, 2005.
114. B. Gunawan, W. Huber, M. Holtrup et al., "Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis, " Cancer Research, vol. 61, no. 21, pp. 7731-7738, 2001.
115. J. C. Presti Jr., M.Wilhelm, V. Reuter, P. Russo, R.Motzer, and F. Waldman, "Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney, " The Journal of Urology, vol. 167, no. 3, pp. 1464-1468, 2002.
116. D. Schullerus, J. Herbers, J. Chudek, H. Kanamaru, and G. Kovacs, "Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas, " Journal of Pathology, vol. 183, no. 2, pp. 151-155, 1997.
117. J. la Rochelle, T. Klatte, A. Dastane et al., "Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma, " Cancer, vol. 116, no. 20, pp. 4696-4702, 2010.
118. B. Grady, R. Goharderakhshan, J. Chang et al., "Frequently deleted loci on chromosome 9 may harbor several tumor suppressor genes in human renal cell carcinoma, " Journal of Urology, vol. 166, no. 3, pp. 1088-1092, 2001.
119. P. Schraml, K. Struckmann, R. Bednar et al., "CDKN2A mutation analysis, protein expression, and deletion mapping of chromosome 9p conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A, " American Journal of Pathology, vol. 158, no. 2, pp. 593-601, 2001.
120. D. de Oliveira, M. F. Dall'Oglio, S. T. Reis et al., "Chromosome 9p deletions are an independent predictor of tumor progression following nephrectomy in patients with localized clear cell renal cell carcinoma, " Urologic Oncology, vol. 32, no. 5, pp. 601-606, 2014.
121. F. A. Monzon, K. Alvarez, L. Peterson et al., "Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis, " Modern Pathology, vol. 24, no. 11, pp. 1470-1479, 2011.
122. W. H. Liggett Jr. and D. Sidransky, "Role of the p16 tumour suppressor gene in cancer, " Journal of Clinical Oncology, vol. 16, no. 3, pp. 1197-1206, 1998.
123. Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of clear cell renal cell carcinoma, " Nature, vol. 499, no. 7456, pp. 43-49, 2013.
124. H. Guo, P. German, S. Bai et al., "The PI3K/AKT pathway and renal cell carcinoma, " Journal of Genetics and Genomics, 2015.
125. R. Bhatnagar and B. A. Alexiev, "Renal-cell carcinomas in endstage kidneys: a clinicopathological study with emphasis on clear-cell papillary renal-cell carcinoma and acquired cystic kidney disease-associated carcinoma, " International Journal of Surgical Pathology, vol. 20, no. 1, pp. 19-28, 2012.
126. S. Gobbo, J. N. Eble, D. J. Grignon et al., "Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity, " American Journal of Surgical Pathology, vol. 32, no. 8, pp. 1239-1245, 2008.
127. J. Adam, J. Couturier, V. Molinié, A. Vieillefond, and M. Sibony, "Clear-cell papillary renal cell carcinoma: 24 cases of a distinct low-grade renal tumour and a comparative genomic hybridization array study of seven cases, " Histopathology, vol. 58, no. 7, pp. 1064-1071, 2011.
128. H. Aydin, L. Chen, L. Cheng et al., "Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney, " American Journal of Surgical Pathology, vol. 34, no. 11, pp. 1608-1621, 2010.
129. S. M. Rohan, Y. Xiao, Y. Liang et al., "Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxiainducible factor pathway-related proteins, " Modern Pathology, vol. 24, no. 9, pp. 1207-1220, 2011.
130. B. Delahunt and J. N. Eble, "Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors, " Modern Pathology, vol. 10, no. 6, pp. 537-544, 1997.
131. G. Pignot, C. Elie, S. Conquy et al., "Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification, " Urology, vol. 69, no. 2, pp. 230-235, 2007.
132. I. Balint, A. Szponar, A. Jauch, and G. Kovacs, "Trisomy 7 and 17 mark papillary renal cell tumours irrespectively of variation of the phenotype, " Journal of Clinical Pathology, vol. 62, no. 10, pp. 892-895, 2009.
133. P. S. Amare, C. Varghese, S. H. Bharde et al., "Proliferating cell nuclear antigen and epidermal growth factor receptor (EGFr) status in renal cell carcinoma patients with polysomy of chromosome 7, " Cancer Genetics and Cytogenetics, vol. 125, no. 2, pp. 139-146, 2001.
134. C. L. Corless, H. Aburatani, J. A. Fletcher, D. E. Housman, M. B. Amin, and D. S. Weinberg, "Papillary renal cell carcinoma: quantitation of chromosomes 7 and 17 by FISH, analysis of chromosome 3p for LOH, and DNA ploidy, " Diagnostic Molecular Pathology, vol. 5, no. 1, pp. 53-64, 1996.
135. M. Brunelli, J. N. Eble, S. Zhang, G. Martignoni, and L. Cheng, "Gains of chromosomes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: a fluorescent in situ hybridization study, " Modern Pathology, vol. 16, no. 10, pp. 1053-1059, 2003.
136. J. Pailoor, R.Rajandram, N.Y.Yap, K. L.Ng, Z.Wang, andK. R. Iyengar, "Chromosome 7 aneuploidy in clear cell and papillary renal cell carcinoma: detection using silver in situ hybridization technique, " Indian Journal of Pathology and Microbiology, vol. 56, no. 2, pp. 98-102, 2013.
137. T. Klatte, A. J. Pantuck, J. W. Said et al., "Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma, " Clinical Cancer Research, vol. 15, no. 4, pp. 1162-1169, 2009.
138. B. Gunawan, A. Von Heydebreck, T. Fritsch et al., "Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors, " Cancer Research, vol. 63, no. 19, pp. 6200-6205, 2003.
139. J. Fischer, G. Palmedo, R. Von Knobloch et al., "Duplication and overexpression of themutant allele of theMET proto-oncogene in multiple hereditary papillary renal cell tumours, " Oncogene, vol. 17, no. 6, pp. 733-739, 1998.
140. Z. Zhuang, W.-S. Park, S. Pack et al., "Trisomy 7-harbouring non-randomduplication of themutantMET allele in hereditary papillary renal carcinomas, " Nature Genetics, vol. 20, no. 1, pp. 66-69, 1998.
141. I. A. Lubensky, L. Schmidt, Z. Zhuang et al., "Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype, " American Journal of Pathology, vol. 155, no. 2, pp. 517-526, 1999.
142. S. L. OrganandM. S. Tsao, "Anoverviewof the c-METsignaling pathway, " Therapeutic Advances in Medical Oncology, vol. 3, no. 1, supplement, pp. S7-S19, 2011.
143. P. Sweeney, A. K. El-Naggar, S.-H. Lin, and L. L. Pisters, "Biological significance of c-met over expression in papillary renal cell carcinoma, " Journal of Urology, vol. 168, no. 1, pp. 51-55, 2002.
144. S. C. Jong, M. K. Kim, W. S. Jin et al., "MET expression in sporadic renal cell carcinomas, " Journal of Korean Medical Science, vol. 21, no. 4, pp. 672-677, 2006.
145. Y. Miyata, H. Kanetake, and S. Kanda, "Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma, " Clinical Cancer Research, vol. 12, no. 16, pp. 4876-4881, 2006.
146. G. T. Gibney, S. A. Aziz, R. L. Camp et al., "c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma, " Annals ofOncology, vol. 24, no. 2, pp. 343-349, 2013.
147. T. K. Choueiri, U. Vaishampayan, J. E. Rosenberg et al., "Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patientswith papillary renal cell carcinoma, " Journal of Clinical Oncology, vol. 31, no. 2, pp. 181-186, 2013.
148. Y.-W. Zhang, "Promise and challenges on the horizon of MET-targeted cancer therapeutics, " World Journal of Biological Chemistry, vol. 6, no. 2, pp. 16-27, 2015.
149. M.-H. Wei, O. Toure, G. M. Glenn et al., "Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer, " Journal of Medical Genetics, vol. 43, no. 1, pp. 18-27, 2006.
150. R. L. Grubb III, M. E. Franks, J. Toro et al., "Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer, " Journal of Urology, vol. 177, no. 6, pp. 2074-2080, 2007.
151. M. J. Merino, C. Torres-Cabala, P. Pinto, and W. Marston Linehan, "The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome, "The American Journal of Surgical Pathology, vol. 31, no. 10, pp. 1578-1585, 2007.
152. J. R. Toro, M. L. Nickerson, M.-H. Wei et al., "Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America, " American Journal of Human Genetics, vol. 73, no. 1, pp. 95-106, 2003.
153. D. L. Smit, A. R. Mensenkamp, S. Badeloe et al., "Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germlinemutation analysis, " Clinical Genetics, vol. 79, no. 1, pp. 49-59, 2011.
154. B. Gardie, A. Remenieras, D. Kattygnarath et al., "Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma, " Journal ofMedical Genetics, vol. 48, no. 4, pp. 226-234, 2011.
155. J. S. Isaacs, Y. J. Jung, D. R. Mole et al., "HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability, " Cancer Cell, vol. 8, no. 2, pp. 143-153, 2005.
156. M. Kiuru, R. Lehtonen, J. Arola et al., "Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families, " Cancer Research, vol. 62, no. 16, pp. 4554-4557, 2002.
157. COSMIC Catalogue of somatic mutations in cancer, 2015, http://cancer.sanger.ac.uk/wgs/browse/tissue.
158. F. Jiang, J. Richter, P. Schraml et al., "Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes, " The American Journal of Pathology, vol. 153, no. 5, pp. 1467-1473, 1998.
159. M. Brunelli, S. Gobbo, P. Cossu-Rocca et al., "Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma, " Modern Pathology, vol. 20, no. 3, pp. 303-309, 2007.
160. G.Kovacs, L. Fuzesi, A. Emanuel, andH.-F.Kung, "Cytogenetics of papillary renal cell tumors, " Genes Chromosomes and Cancer, vol. 3, no. 4, pp. 249-255, 1991.
161. M. Kovac, C.Navas, S.Horswell et al., "Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution, " Nature Communications, vol. 6, article 6336, 2015.
162. M. C. Jaramillo and D. D. Zhang, "The emerging role of the Nrf2-Keap1 signaling pathway in cancer, " Genes&Development, vol. 27, no. 20, pp. 2179-2191, 2013.
163. L. E. Moore, M. L. Nickerson, P. Brennan et al., "Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors, " PLoS Genetics, vol. 7, no. 10, Article ID e1002312, 2011.
164. M. L. Nickerson, E. Jaeger, Y. Shi et al., "Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors, " Clinical Cancer Research, vol. 14, no. 15, pp. 4726-4734, 2008.
165. R. E. Banks, P. Tirukonda, C. Taylor et al., "Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationshipwith clinical variables in sporadic renal cancer, " Cancer Research, vol. 66, no. 4, pp. 2000-2011, 2006.
166. S. Kvasha, V. Gordiyuk, A. Kondratov et al., "Hypermethylation of the 5CpG island of the FHIT gene in clear cell renal carcinomas, " Cancer Letters, vol. 265, no. 2, pp. 250-257, 2008.
167. W.-G.Deng, M. Nishizaki, B. Fang, J. A. Roth, and L. Ji, "Induction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells, " Biochemical and Biophysical Research Communications, vol. 355, no. 4, pp. 993-999, 2007.
168. J. C. Saldivar, H. Shibata, and K. Huebner, "Pathology and biology associated with the fragile FHIT gene and gene product, " Journal of Cellular Biochemistry, vol. 109, no. 5, pp. 858-865, 2010.
169. C. Sevignani, G. A. Calin, R. Cesari et al., "Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines, " Cancer Research, vol. 63, no. 6, pp. 1183-1187, 2003.
170. L. Roz, M. Gramegna, H. Ishii, C. M. Croce, and G. Sozzi, "Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 6, pp. 3615-3620, 2002.
171. K. Dreijerink, E. Braga, I. Kuzmin et al., "The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 13, pp. 7504-7509, 2001.
172. C. Simone, "SWI/SNF: the crossroads where extracellular signaling pathways meet chromatin, " Journal of Cellular Physiology, vol. 207, no. 2, pp. 309-314, 2006.
173. J.-H. Park, E.-J. Park, S.-K. Hur, S. Kim, and J. Kwon, "Mammalian SWI/SNF chromatin remodeling complexes are required to prevent apoptosis after DNA damage, " DNA Repair, vol. 8, no. 1, pp. 29-39, 2009.
174. Z.M. Eletr andK. D.Wilkinson, "Anemergingmodel for BAP1's role in regulating cell cycle progression, " Cell Biochemistry and Biophysics, vol. 60, no. 1-2, pp. 3-11, 2011.
175. G. Duns, E. D. van Berg, I. van Duivenbode et al., "Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma, " Cancer Research, vol. 70, no. 11, pp. 4287-4291, 2010.
176. X. Niu, T. Zhang, L. Liao et al., "The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C, " Oncogene, vol. 31, no. 6, pp. 776-786, 2012.
177. D. Schullerus, R. von Knobloch, J. Chudek, J. Herbers, and G. Kovacs, "Microsatellite analysis reveals deletion of a large region at chromosome 8p in conventional renal cell carcinoma, " International Journal of Cancer, vol. 80, no. 1, pp. 22-24, 1999.
178. K. Mitsumori, J. M. Kittleson, N. Itoh et al., "Chromosome 14q LOH in localized clear cell renal cell carcinoma, " Journal of Pathology, vol. 198, no. 1, pp. 110-114, 2002.
179. A. Alimov, B. Sundelin, N. Wang, C. Larsson, and U. Bergerheim, "Loss of 14q31-q32.2 in renal cell carcinoma is associated with high malignancy grade and poor survival, " International Journal of Oncology, vol. 25, no. 1, pp. 179-185, 2004.
180. H. Kaku, S. Ito, S. Ebara et al., "Positive correlation between allelic loss at chromosome 14q24-31 and poor prognosis of patients with renal cell carcinoma, " Urology, vol. 64, no. 1, pp. 176-181, 2004.
181. J. An, J. Choi, B. K. Shin, A. Kim, H. K. Kim, and I. Kim, "Chromogenic in situ hybridization detection of chromosome 7 and 17 abnormalities in renal cell carcinomas and comparison to flow cytometric DNA ploidy patterns, " Basic and Applied Pathology, vol. 1, no. 2, pp. 66-71, 2008.
182. D. J. Lager, B. J. Huston, T. G. Timmerman, and S. M. Bonsib, "Papillary renal tumors: morphologic, cytochemical, and genotypic features, " Cancer, vol. 76, no. 4, pp. 669-673, 1995.
183. M. D. Hughson, K. Dickman, S. A. Bigler, A. M. Meloni, and A. A. Sandberg, "Clear-cell and papillary carcinoma of the kidney: an analysis of chromosome 3, 7, and 17 abnormalities by microsatellite amplification, cytogenetics, and fluorescence in situ hybridization, "CancerGenetics andCytogenetics, vol. 106, no. 2, pp. 93-104, 1998.
184. W. Yu, W. Zhang, Y. Jiang et al., "Clinicopathological, genetic, ultrastructural characterizations and prognostic factors of papillary renal cell carcinoma: new diagnostic and prognostic information, " Acta Histochemica, vol. 115, no. 5, pp. 452-459, 2013.
185. M. E. Sanders, R. Mick, J. E. Tomaszewski, and F. G. Barr, "Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma, " The American Journal of Pathology, vol. 161, no. 3, pp. 997-1005, 2002.
186. X. J. Yang, M. H. Tan, H. L.Kimet al., "Amolecular classification of papillary renal cell carcinoma, " Cancer Research, vol. 65, no. 13, pp. 5628-5637, 2005.
187. R. F. Schwerdtle, S. Storkel, C. Neuhaus et al., "Allelic losses at chromosomes 1p, 2p, 6p, 10p, 13q, 17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma, " Cancer Research, vol. 56, no. 13, pp. 2927-2930, 1996.
188. A. Nagy, I. Buzogany, and G. Kovacs, "Microsatellite allelotyping differentiates chromophobe renal cell carcinomas from renal oncocytomas and identifies new genetic changes, " Histopathology, vol. 44, no. 6, pp. 542-546, 2004.
189. M. Brunelli, J. N. Eble, S. Zhang, G. Martignoni, B. Delahunt, and L. Cheng, "Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma, " Modern Pathology, vol. 18, no. 2, pp. 161-169, 2005.
190. M. Sperga, P.Martinek, T. Vanecek et al., "Chromophobe renal cell carcinoma - chromosomal aberration variability and its relation to Paner grading system: an array CGH and FISH analysis of 37 cases, " Virchows Archiv, vol. 463, no. 4, pp. 563-573, 2013.
191. S. Gad, S. H. Lefèvre, S. K. Khoo et al., "Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma, " British Journal of Cancer, vol. 96, no. 2, pp. 336-340, 2007.
192. C. Davis, C. J. Ricketts, M. Wang et al., "The somatic genomic landscape of chromophobe renal cell carcinoma, " Cancer Cell, vol. 26, no. 3, pp. 319-330, 2014.
193. H. Contractor, M. Zariwala, P. Bugert, J. Zeisler, and G. Kovacs, "Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour, " Journal of Pathology, vol. 181, no. 2, pp. 136-139, 1997.
194. M.M. Picken, B. Chyna, R. C. Flanigan, and J. M. Lee, "Analysis of chromosome 1p abnormalities in renal oncocytomas by loss of heterozygosity studies: correlation with conventional cytogenetics and fluorescence in situ hybridization, " American Journal of Clinical Pathology, vol. 129, no. 3, pp. 377-382, 2008.
195. V. Lindgren, G. P. Paner, A. Omeroglu et al., "Cytogenetic analysis of a series of 13 renal oncocytomas, " Journal of Urology, vol. 171, no. 2, pp. 602-604, 2004.
196. J. A. Brown, S. Takahashi, A. Alcaraz et al., "Fluorescence in situ hybridization analysis of renal oncocytoma reveals frequent loss of chromosomes Y and 1, " Journal of Urology, vol. 156, no. 1, pp. 31-35, 1996.
197. L. Füzesi, D. Frank, C. Nguyen, R.-H. Ringert, H. Bartels, and B. Gunawan, "Losses of 1p and chromosome 14 in renal oncocytomas, " Cancer Genetics and Cytogenetics, vol. 160, no. 2, pp. 120-125, 2005.
198. W. R. Sukov, R. P. Ketterling, D. J. Lager et al., "CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma, " Human Pathology, vol. 40, no. 9, pp. 1296-1303, 2009.
199. E. Van Den Berg, T. Dijkhuizen, S. Störkel et al., "Chromosomal changes in renal oncocytomas: evidence that t(5;11)(q35;q13) may characterize a second subgroup of oncocytomas, " Cancer Genetics and Cytogenetics, vol. 79, no. 2, pp. 164-168, 1995.
200. L. Fuzesi, B. Gunawan, S. Braun et al., "Cytogenetic analysis of 11 renal oncocytomas: further evidence of structural rearrangements of 11q13 as a characteristic chromosomal anomaly, " Cancer Genetics and Cytogenetics, vol. 107, no. 1, pp. 1-6, 1998.
201. F. Becker, K. Junker, M. Parr et al., "Collecting duct carcinomas represent a unique tumour entity based on genetic alterations, " PLoS ONE, vol. 8, no. 10, Article IDe78137, 2013.
202. L. Fuzesi, M. Cober, and C. Mittermayer, "Collecting duct carcinoma: cytogenetic characterization, " Histopathology, vol. 21, no. 2, pp. 155-160, 1992.
203. L. S. Schmidt and W. M. Linehan, "Hereditary leiomyomatosis and renal cell carcinoma, " International Journal of Nephrology and Renovascular Disease, vol. 7, pp. 253-260, 2014.
204. C. P. Pavlovich, R. L. Grubb III, K. Hurley et al., "Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome, "The Journal of Urology, vol. 173, no. 5, pp. 1482-1486, 2005.
205. L. S. Schmidt, M. L. Nickerson, M. B. Warren et al., "Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome, " The American Journal of Human Genetics, vol. 76, no. 6, pp. 1023-1033, 2005.
206. C. P. Pavlovich, M.M.Walther, R. A. Eyler et al., "Renal tumors in the Birt-Hogg-Dubé syndrome, " The American Journal of Surgical Pathology, vol. 26, no. 12, pp. 1542-1552, 2002.
207. A. Szponar, M. V. Yusenko, and G. Kovacs, "High-resolution array CGH of metanephric adenomas: lack of DNA copy number changes, " Histopathology, vol. 56, no. 2, pp. 212-216, 2010.
208. R. Drut, R. M. Drut, and C. Ortolani, "Metastatic metanephric adenomawith foci of papillary carcinoma in a child: a combined histologic, immunohistochemical, and FISH study, " International Journal of Surgical Pathology, vol. 9, no. 3, pp. 241-247, 2001.
209. A. A. Renshaw, D. R. Freyer, and Y. A. Hammers, "Metastatic metanephric adenoma in a child, " American Journal of Surgical Pathology, vol. 24, no. 4, pp. 570-574, 2000.
210. J. A. Brown, K. L. Anderl, T. J. Borell, J. Qian, D. G. Bostwick, andR. B. Jenkins, "Simultaneous chromosome 7 and17 gainand sex chromosome loss provide evidence that renal metanephric adenoma is related to papillary renal cell carcinoma, " Journal of Urology, vol. 158, no. 2, pp. 370-374, 1997.
211. C.-C. Pan and J. I. Epstein, "Detection of chromosome copy number alterations inmetanephric adenomas by array comparative genomic hybridization, " Modern Pathology, vol. 23, no. 12, pp. 1634-1640, 2010.
212. M. Brunelli, J.N. Eble, S. Zhang, G. Martignoni, and L. Cheng, "Metanephric adenoma lacks the gains of chromosomes 7 and 17 and loss of Y that are typical of papillary renal cell carcinoma and papillary adenoma, " Modern Pathology, vol. 16, no. 10, pp. 1060-1063, 2003.
213. M. Stumm, A. Koch, P. F. Wieacker et al., "Partial monosomy 2p as the single chromosomal anomaly in a case of renal metanephric adenoma, " Cancer Genetics and Cytogenetics, vol. 115, no. 1, pp. 82-85, 1999.
214. T. Pesti, F. Sükösd, E.C. Jones, andG. Kovacs, "Mapping a tumor suppressor gene to chromosome 2p13 in metanephric adenoma by microsatellite allelotyping, " Human Pathology, vol. 32, no. 1, pp. 101-104, 2001.
215. B. Dadone, D. Ambrosetti, X. Carpentier et al., "A renal metanephric adenoma showing both a 2p16-24 deletion and BRAF V600E mutation: a synergistic role for a tumor suppressor gene on chromosome 2p and BRAF activation?" Cancer Genetics, vol. 206, no. 9-10, pp. 347-352, 2013.
216. T. K. Choueiri, J. Cheville, E. Palescandolo et al., "BRAF mutations in metanephric adenoma of the kidney, " European Urology, vol. 62, no. 5, pp. 917-922, 2012.
217. S. Gattenlöhner, B. Etschmann, H. Riedmiller, and H.-K. Müller-Hermelink, "Lack of KRAS and BRAFmutation in renal cell carcinoma, " European Urology, vol. 55, no. 6, pp. 1490-1491, 2009.
218. A. Nagy, I. Balint, and G. Kovacs, "Frequent allelic changes at chromosome 7q34but lackofmutationof theBRAFinpapillary renal cell tumors, " International Journal of Cancer, vol. 106, no. 6, pp. 980-981, 2003.
219. E. W. Joseph, C. A. Pratilas, P. I. Poulikakos et al., "The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 33, pp. 14903-14908, 2010.
220. J. N. Eble, Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs, IARC, 2004.
221. S. S. Shen, J. Y. Ro, P. Tamboli et al., "Mucinous tubular and spindle cell carcinoma of kidney is probably a variant of papillary renal cell carcinoma with spindle cell features, " Annals of Diagnostic Pathology, vol. 11, no. 1, pp. 13-21, 2007.
222. P. Cossu-Rocca, J. N. Eble, B. Delahunt et al., "Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma, " Modern Pathology, vol. 19, no. 4, pp. 488-493, 2006.
223. N. Kuroda, T. Naroda, M. Tamura et al., "High-grade mucinous tubular and spindle cell carcinoma: comparative genomic hybridization study, " Annals of Diagnostic Pathology, vol. 15, no. 6, pp. 472-475, 2011.
224. P. Brandal, A. K. Lie, A. Bassarova et al., "Genomic aberrations in mucinous tubular and spindle cell renal cell carcinomas, " Modern Pathology, vol. 19, no. 2, pp. 186-194, 2006.
225. K. Okoń, A. Klimkowska, A. Pawelec, Z. Dobrowolski, Z. Kohla, and J. Stachura, "Immunophenotype and cytogenetics of mucinous tubular and spindle cell carcinoma of the kidney, " Polish Journal of Pathology, vol. 58, no. 4, pp. 227-233, 2007.
226. Y. Zhang, X. Yong, Q.Wu et al., "Mucinous tubular and spindle cell carcinoma and solid variant papillary renal cell carcinoma: a clinicopathologic comparative analysis of four cases with similar molecular genetics datum, " Diagnostic Pathology, vol. 9, no. 1, article 194, 2014.
227. C. Rakozy, G. E. Schmahl, S. Bogner, and S. Störkel, "Low-grade tubular-mucinous renal neoplasms: morphologic, immunohistochemical, and genetic features, " Modern Pathology, vol. 15, no. 11, pp. 1162-1171, 2002.
228. P. Argani, S. Olgac, S. K. Tickoo et al., "Xp11 Translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum, " American Journal of Surgical Pathology, vol. 31, no. 8, pp. 1149-1160, 2007.
229. Y. Komai, M. Fujiwara, Y. Fujii et al., "Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry, " Clinical Cancer Research, vol. 15, no. 4, pp. 1170-1176, 2009.
230. H. B. Armah and A. V. Parwani, "Xp11.2 translocation renal cell carcinoma, " Archives of Pathology and Laboratory Medicine, vol. 134, no. 1, pp. 124-129, 2010.
231. P. Ahluwalia, B. Nair, and G. Kumar, "Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: a rare case report with review of the literature, " Case Reports in Urology, vol. 2013, Article ID 810590, 4 pages, 2013.
232. P. Argani, P. Lal, B. Hutchinson, M. Y. Lui, V. E. Reuter, and M. Ladanyi, "Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay, "The American Journal of Surgical Pathology, vol. 27, no. 6, pp. 750-761, 2003.
233. C. G. Przybycin, A. M. Cronin, F. Darvishian et al., "Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution, "The American Journal of Surgical Pathology, vol. 35, no. 7, pp. 962-970, 2011.
234. S. D. W. Beck, M. I. Patel, M. E. Snyder et al., "Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma, " Annals of Surgical Oncology, vol. 11, no. 1, pp. 71-77, 2004.
235. M. B. Amin, G. P. Paner, I. Alvarado-Cabrero et al., "Chromophobe renal cell carcinoma: Histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases, " American Journal of Surgical Pathology, vol. 32, no. 12, pp. 1822-1834, 2008.
236. M. L. Nickerson, M. B.Warren, J. R. Toro et al., "Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome, " Cancer Cell, vol. 2, no. 2, pp. 157-164, 2002.
237. M. B. Warren, C. A. Torres-Cabala, M. L. Turner et al., "Expression of Birt-Hogg-Dube gene mRNA in normal and neoplastic human tissues, " Modern Pathology, vol. 17, no. 8, pp. 998-1011, 2004.
238. C. D. Vocke, Y. Yang, C. P. Pavlovich et al., "High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors, " Journal of the National Cancer Institute, vol. 97, no. 12, pp. 931-935, 2005.
239. J. Chen, K. Futami, D. Petillo et al., "Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia, " PLoSONE, vol. 3, no. 10, Article IDe3581, 2008.
240. M. Baba, M. Furihata, S.-B. Hong et al., "Kidney-targeted Birt-Hogg-Dubé gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys, " Journal of the National Cancer Institute, vol. 100, no. 2, pp. 140-154, 2008.
241. A. Nagy, D. Zoubakov, Z. Stupar, and G. Kovacs, "Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma, " International Journal of Cancer, vol. 109, no. 3, pp. 472-475, 2004.
242. T. Murakami, F. Sano, Y. Huang et al., "Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma, " Journal of Pathology, vol. 211, no. 5, pp. 524-531, 2007.
243. M. Brunelli, B.Delahunt, S. Gobbo et al., "Diagnosticusefulness of fluorescent cytogenetics in differentiating chromophobe renal cell carcinoma from renal oncocytoma: a validation study combiningmetaphase and interphase analyses, "American Journal of Clinical Pathology, vol. 133, no. 1, pp. 116-126, 2010.
244. M. V. Yusenko, R. P. Kuiper, T. Boethe et al., "High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas, " BMC Cancer, vol. 9, article 152, 2009.
245. D. P. Liu, H. Song, and Y. Xu, "A common gain of function of p53 cancer mutants in inducing genetic instability, " Oncogene, vol. 29, no. 7, pp. 949-956, 2010.
246. F. Sükösd, B. Digon, J. Fischer, T. Pietsch, and G. Kovacs, "Allelic loss at 10q23.3 but lack of mutation of PTEN/MMAC1 in chromophobe renal cell carcinoma, " Cancer Genetics and Cytogenetics, vol. 128, no. 2, pp. 161-163, 2001.
247. G. P. Paner, M. B. Amin, I. Alvarado-Cabrero et al., "A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with fuhrman nuclear grade, " The American Journal of Surgical Pathology, vol. 34, no. 9, pp. 1233-1240, 2010.
248. M. H. Tan, C. F. Wong, H. L. Tan et al., "Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma, " BMC Cancer, vol. 10, article 196, 2010.
249. J. D. Oxley, J. Sullivan, A. Mitchelmore, and D. A. Gillatt, "Metastatic renal oncocytoma, " Journal of Clinical Pathology, vol. 60, no. 6, pp. 720-722, 2007.
250. J. S. Jhang, G. Narayan, V. V. V. S. Murty, and M. M. Mansukhani, "Renal oncocytomas with 11q13 rearrangements: cytogenetic, molecular, and immunohistochemical analysis of cyclin D1, " Cancer Genetics and Cytogenetics, vol. 149, no. 2, pp. 114-119, 2004.
251. S. Zanssen, B. Gunawan, L. Fuzesi, D. Warburton, and E. A. Schon, "Renal oncocytomas with rearrangements involving 11q13 contain breakpoints near CCND1, " Cancer Genetics and Cytogenetics, vol. 149, no. 2, pp. 120-124, 2004.
252. T. Dijkhuizen, E. van den Berg, S. Storkel et al., "Renal oncocytoma with t(5;12;11), der(1)1;8) and add(19): 'true' oncocytoma or chromophobe adenoma?" International Journal of Cancer, vol. 73, no. 4, pp. 521-524, 1997.
253. N. Tokuda, S.Naito, O.Matsuzaki, Y.Nagashima, S. Ozono, and T. Igarashi, "Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan, " The Journal of Urology, vol. 176, no. 1, pp. 40-43, 2006.
254. M. May, V. Ficarra, S. F. Shariat et al., "Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model, " Journal of Urology, vol. 190, no. 2, pp. 458-463, 2013.
255. M. Schoenberg, P. Cairns, J. D. Brooks et al., "Frequent loss of chromosome arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney, " Genes Chromosomes and Cancer, vol. 12, no. 1, pp. 76-80, 1995.
256. G. Steiner, P. Cairns, T. J. Polascik et al., "High-densitymapping of chromosomal arm 1q in renal collecting duct carcinoma: region of minimal deletion at 1q32.1-32.2, " Cancer Research, vol. 56, no. 21, pp. 5044-5046, 1996.
257. A.Orsola, I. Trias, C. X. Raventós, I. Español, L. Cecchini, and I. Orsola, "Renal collecting (Bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma, " Urology, vol. 65, no. 1, pp. 49-54, 2005.
258. R. Gupta, A. Billis, R. B. Shah et al., "Carcinoma of the collecting ducts of bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship, " American Journal of Surgical Pathology, vol. 36, no. 9, pp. 1265-1278, 2012.
259. M. A. Swartz, J. Karth, D. T. Schneider, R. Rodriguez, J. B. Beckwith, and E. J. Perlman, "Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications, " Urology, vol. 60, no. 6, pp. 1083-1089, 2002.
260. Z.Gatalica, S. L. Lilleberg, F. A.Monzon et al., "Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes, " Human Pathology, vol. 42, no. 12, pp. 1979-1988, 2011.
261. M. B. Amin, G. T. MacLennan, R. Gupta et al., "Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma, " The American Journal of Surgical Pathology, vol. 33, no. 3, pp. 384-392, 2009.
262. G. T.Maclennan, G.M. Farrow, andD. G. Bostwick, "Low-grade collecting duct carcinoma of the kidney: report of 13 cases of low-grade mucinous tubulocystic renal carcinoma of possible collecting duct origin, " Urology, vol. 50, no. 5, pp. 679-684, 1997.
263. M. Zhou, X. J. Yang, J. I. Lopez et al., "Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification, " American Journal of Surgical Pathology, vol. 33, no. 12, pp. 1840-1849, 2009.
264. T.O. Al-Hussain, L. Cheng, S. Zhang, and J. I. Epstein, "Tubulocystic carcinoma of the kidney with poorly differentiated foci: a series of 3 cases with fluorescence in situ hybridization analysis, " Human Pathology, vol. 44, no. 7, pp. 1406-1411, 2013.